Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells
that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) …

Synthetic oligodeoxynucleotides (ODNs) that contain immunostimulatory CpG motifs trigger
an immunomodulatory cascade that involves B and T cells, natural killer cells and …

The immature plasmacytoid dendritic cell (PDC) is identical with the principal type I IFN‐
producing cell upon viral infection. Oligodeoxynucleotides which contain unmethylated CpG …

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically
designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid …

The development of adjuvants will represent a major challenge for this century. Indeed the
need for safer vaccines leads to the development of a new generation of antigens like …

The present invention relates generally to adjuvants, and in particular to methods and
products utilizing a synergistic combination of immunostimulatory oligonucleotides having at …

Two different CpG oligonucleotides (ODN) were used to study the regulation of type I IFN in
human plasmacytoid dendritic cells (PDC): ODN 2216, a CpG-A ODN, known to induce high …

Detailed information of human B cell activation via TLR may lead to a better understanding
of B cell involvement in autoimmunity and malignancy. In this study we identified a …

Background Prophylactic and therapeutic vaccines often depend upon a strong activation of
the innate immune system to drive a potent adaptive immune response, often mediated by a …

The present invention relates to Synergistic combinations of immunostimulatory CpG
oligonucleotides and immunopo tentiating cytokines. In particular, the invention relates to …